A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers

Andrea Cercek(Memorial Sloan Kettering Cancer Center), Walid K. Chatila(Memorial Sloan Kettering Cancer Center), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Henry Walch(Memorial Sloan Kettering Cancer Center), Gustavo dos Santos Fernandes(Memorial Sloan Kettering Cancer Center), Asha Krishnan(Memorial Sloan Kettering Cancer Center), Lerie Palmaira(Memorial Sloan Kettering Cancer Center), Anna Maio(Memorial Sloan Kettering Cancer Center), Yelena Kemel(Memorial Sloan Kettering Cancer Center), Preethi Srinivasan(Memorial Sloan Kettering Cancer Center), Chaitanya Bandlamudi(Memorial Sloan Kettering Cancer Center), Erin Salo‐Mullen(Memorial Sloan Kettering Cancer Center), Prince Ray Tejada(Memorial Sloan Kettering Cancer Center), Kimeisha Belanfanti(Memorial Sloan Kettering Cancer Center), Jesse Galle(Memorial Sloan Kettering Cancer Center), Joseph Vijai(Memorial Sloan Kettering Cancer Center), Neil H. Segal(Memorial Sloan Kettering Cancer Center), Anna M. Varghese(Memorial Sloan Kettering Cancer Center), Diane Reidy‐Lagunes(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Efsevia Vakiani(Memorial Sloan Kettering Cancer Center), Sebastián Mondaca(Memorial Sloan Kettering Cancer Center), Robin B. Mendelsohn(Memorial Sloan Kettering Cancer Center), Melissa Lumish(Memorial Sloan Kettering Cancer Center), Felix Steinruecke(Memorial Sloan Kettering Cancer Center), Nancy E. Kemeny(Memorial Sloan Kettering Cancer Center), Louise C. Connell(Memorial Sloan Kettering Cancer Center), Karuna Ganesh(Memorial Sloan Kettering Cancer Center), Arnold J. Markowitz(Memorial Sloan Kettering Cancer Center), Garrett M. Nash(Memorial Sloan Kettering Cancer Center), José G. Guillem(Memorial Sloan Kettering Cancer Center), J. Joshua Smith(Memorial Sloan Kettering Cancer Center), Phillip Paty(Memorial Sloan Kettering Cancer Center), Liying Zhang(Memorial Sloan Kettering Cancer Center), Diana Mandelker(Memorial Sloan Kettering Cancer Center), Ozge Ceyhan‐Birsoy(Memorial Sloan Kettering Cancer Center), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Martin R. Weiser(Memorial Sloan Kettering Cancer Center), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Julio García‐Aguilar(Memorial Sloan Kettering Cancer Center), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Zsofia K. Stadler(Memorial Sloan Kettering Cancer Center)
JNCI Journal of the National Cancer Institute
July 15, 2021
Cited by 187Open Access
Full Text

Abstract

BACKGROUND: The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset colorectal cancer (AO-CRC). METHODS: Clinical, histopathologic, and genomic characteristics of EO-CRC patients (2014-2019), divided into age 35 years and younger and 36-49 years at diagnosis, were compared with AO-CRC (50 years and older). Patients with mismatch repair deficient tumors, CRC-related hereditary syndromes, and inflammatory bowel disease were excluded from all but the germline analysis. All statistical tests were 2-sided. RESULTS: In total, 759 patients with EO-CRC (35 years, n = 151; 36-49 years, n = 608) and AO-CRC (n = 687) were included. Left-sided tumors (35 years and younger = 80.8%; 36-49 years = 83.7%; AO = 63.9%; P < .001 for both comparisons), rectal bleeding (35 years and younger = 41.1%; 36-49 years = 41.0%; AO = 25.9%; P = .001 and P < .001, respectively), and abdominal pain (35 years and younger = 37.1%; 36-49 years = 34.0%; AO = 26.8%; P = .01 and P = .005, respectively) were more common in EO-CRC. Among microsatellite stable tumors, we found no differences in histopathologic tumor characteristics. Initially, differences in TP53 and Receptor Tyrosine Kinase signaling pathway (RTK-RAS)alterations were noted by age. However, on multivariate analysis including somatic gene analysis and tumor sidedness, no statistically significant differences at the gene or pathway level were demonstrated. Among advanced microsatellite stable CRCs, chemotherapy response and survival were equivalent by age cohorts. Pathogenic germline variants were identified in 23.3% of patients 35 years and younger vs 14.1% of AO-CRC (P = .01). CONCLUSIONS: EO-CRCs are more commonly left-sided and present with rectal bleeding and abdominal pain but are otherwise clinically and genomically indistinguishable from AO-CRCs. Aggressive treatment regimens based solely on the age at CRC diagnosis are not warranted.


Related Papers

No related papers found

Powered by citation graph analysis